Application Of Next Generation Sequencing To Address Clinical Problems In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$463,652.00
Summary
Cancer is the cause of 1 in 8 deaths worldwide. Cancer occurs due to errors or mutations in the DNA of normal cells. The mutations may cause the cells to grow incorrectly and become cancer. I will identify the mutations or errors in tumour cells. This will tell us: i) How the tumour started and continued to grow ii) How to treat the tumour cells to kill the cancer The work will involve a variety of cancer types including mesothelioma, melanoma, oesophageal, pancreatic and breast cancer.
Computational Methods For The Analysis Of Next Generation Sequence Data In Human Disease
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
Modern DNA sequencing technologies generate data at an unprecedented rate, providing the opportunity to develop deep insights into human disease. We can now sequence a tumour genome in a matter of weeks, or assay epigenetic marks in the malaria parasite genome, but these data raise new analysis challenges requiring new statistical and computational methods to solve. This fellowship will support the development of such new methods and will contribute to basic discoveries in human disease.
Development And Application Of A Novel Technology, CaptureSeq, To Focus Sequencing To Discover Genes In ‘empty’ Genomic Regions Associated With Disease.
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
Dr. Mercer will develop a new technology, CaptureSeq that is able to focus RNA sequencing on targeted regions of interest. This focus gives CaptureSeq an unprecedented sensitivity to discover new genes and regulatory elements in regions of the genome that have been associated with disease but are otherwise barren and empty. This project will thereby uncover both new genes candidates for further disease research and develop a technology with unique and widespread research and clinical potential.